New innovations in cancer therapies have people excited to leave behind the treatments of old, but it might not be time yet to throw away chemotherapy, said Bruce Feinberg, DO, vice president and chief medical officer of Cardinal Health Specialty Solutions.
New innovations in cancer therapies have people excited to leave behind the treatments of old, but it might not be time yet to throw away chemotherapy, said Bruce Feinberg, DO, vice president and chief medical officer of Cardinal Health Specialty Solutions.
Why are people so quick to herald the end of chemotherapy?
There is a great term coined by an economist, which is “the irrational exuberance of our behavior.” And I think that we’re inclined to that as human beings. That we really have so much zest for that which is new, that which is different, that which we often inflate in terms of its value as being more effective, less toxic, lower risk, better return, no longer palliative, now curative. And we’ve conflated all that into these new classes of drugs, which often are as toxic or more toxic than chemotherapy, not necessarily better than in the general population—thought like chemo, they may be in selected populations.
And so, I think it’s just human nature that has led to that. But particularly, because when chemo was the only option, and given its toxicity profile, as many drugs have, it just got this bad rap, that we need to advance, we need to move on, we can do better than this, we don’t need these poisons to be injected into our bodies. But unfortunately, again, there was that negative that was also exaggerated. So, many chemotherapy drugs, when delivered appropriately, don’t carry all that weight, they can be relatively effective in the relevant population, and they may not be terribly toxic.
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Dr Michael Farwell on FDG PET/CT Imaging to Predict Immunotherapy Response in Advanced Melanoma
April 15th 2024Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT imaging to detect metabolic tumor changes in skin cancer.
Read More